Our data show that a large percentage of DLBCL and WM cases that have a MYD88 mutation also harbor a TNFAIP3 loss, 55% DLBCL and 28%, respectively. This evidence concerns the gene TNFAIP3 and diffuse large B-cell lymphoma.